Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
May 2022	65	Global Markets Direct	ASDR-601526

Published: May 2022 - Pages : 65 - Publisher : Global Markets Direct - Report code : ASDR-601526

Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
MorphoSys AG
Ningbo Wenda Pharmaceutical Technology Co Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd

Cancer Immunotherapy: Technologies and Global Markets

This report can be of interest as well:

Cancer Immunotherapy: Technologies and Global Markets

Published: April, 2025 | Report code: ASDR-675808